| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(12 years from now) | |
| US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(12 years from now) | |
|
US10857159 (Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(13 years from now) | |
Lexette is owned by Mayne Pharma.
Lexette contains Halobetasol Propionate.
Lexette has a total of 3 drug patents out of which 0 drug patents have expired.
Lexette was authorised for market use on 24 May, 2018.
Lexette is available in aerosol, foam;topical dosage forms.
Lexette can be used as for the topical treatment of plaque psoriasis in patients 18 years of age and older.
The generics of Lexette are possible to be released after 30 May, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 18, 2024 |
| New Dosage Form(NDF) | May 24, 2021 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of LEXETTE before it's drug patent expiration?
More Information on Dosage
LEXETTE family patents
